KENNEY CHRISTOPHER JOHN
Known title: Chief Medical OfficerCIK: 0001880129
KENNEY CHRISTOPHER JOHN's purchase track record
KENNEY CHRISTOPHER JOHN has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/21/2022 | XENE | $20K | +23.8% | +24.8% | -9.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XENE | ▼ Sell | Open Market | 6,368 | $383K | 8/28/2026 | View on chart |
| XENE | ▼ Sell | Open Market | 700 | $43K | 8/28/2026 | View on chart |
| XENE | ▼ Sell | Open Market | 1,410 | $78K | 3/13/2026 | View on chart |
| XENE | ▲ Buy | Option Exercise | 3,750 | — | 3/12/2026 | View on chart |
| XENE | ▼ Sell | Open Market | 2,771 | $167K | 3/10/2026 | View on chart |
| XENE | ▲ Buy | Option Exercise | 7,500 | — | 3/9/2026 | View on chart |
| XENE | ▼ Sell | Open Market | 700 | $25K | 3/24/2023 | View on chart |
| XENE | ▲ Buy | Open Market | 700 | $20K | 1/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target
Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).